仁和药业
(000650)
| 流通市值：68.97亿 | | | 总市值：72.52亿 |
| 流通股本：13.31亿 | | | 总股本：14.00亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,090,941,027.03 | 1,129,224,010.41 | 3,536,422,014.45 | 2,833,451,760.31 |
| 营业收入 | 2,090,941,027.03 | 1,129,224,010.41 | 3,536,422,014.45 | 2,833,451,760.31 |
| 二、营业总成本 | 1,670,769,053.24 | 892,993,180.85 | 2,913,953,460.09 | 2,337,881,030.25 |
| 营业成本 | 1,338,981,178.91 | 714,756,977.68 | 2,229,233,513.06 | 1,801,340,191.69 |
| 税金及附加 | 21,412,258.92 | 10,127,444.47 | 38,011,612.8 | 26,633,548.97 |
| 销售费用 | 145,730,279.42 | 74,791,943.95 | 345,393,966.88 | 263,387,663.72 |
| 管理费用 | 148,892,803.14 | 86,401,971.7 | 255,855,558.88 | 219,380,428.96 |
| 研发费用 | 15,228,347.8 | 7,452,851 | 45,065,951.51 | 26,403,032.09 |
| 财务费用 | 524,185.05 | -538,007.95 | 392,856.96 | 736,164.82 |
| 其中:利息费用 | 35,006.92 | 18,396.36 | 86,906.3 | 63,140.93 |
| 其中:利息收入 | 822,319.15 | 664,402.07 | 2,695,760.04 | 2,073,900.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 29,539,733.37 | -2,426,648.3 | 25,116,621.86 | -827,369 |
| 加:投资收益 | 15,330,658.7 | 5,498,491.4 | 83,430,024.12 | 38,329,882.06 |
| 资产处置收益 | -41,579.62 | 4,757.02 | 2,048,182.02 | 2,050,698.58 |
| 资产减值损失(新) | -169,209.19 | 661.3 | -129,175,268.45 | 107,491.34 |
| 信用减值损失(新) | -7,721,243.25 | 3,232.1 | -32,539,266.08 | -8,656,206.79 |
| 其他收益 | 6,907,324.38 | 3,721,066.57 | 93,863,226.2 | 90,406,775.28 |
| 四、营业利润 | 464,017,658.18 | 243,032,389.65 | 665,212,074.03 | 616,982,001.53 |
| 加:营业外收入 | 1,752,170.18 | 368,235.42 | 7,096,270.07 | 1,978,432.93 |
| 减:营业外支出 | 901,028.19 | 493,752.41 | 7,411,351.11 | 2,908,090.51 |
| 五、利润总额 | 464,868,800.17 | 242,906,872.66 | 664,896,992.99 | 616,052,343.95 |
| 减:所得税费用 | 109,486,235.68 | 64,676,882.55 | 177,240,243.54 | 146,942,194.74 |
| 六、净利润 | 355,382,564.49 | 178,229,990.11 | 487,656,749.45 | 469,110,149.21 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 355,382,564.49 | 178,229,990.11 | 487,656,749.45 | 469,110,149.21 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 291,949,140.28 | 140,374,777.74 | 393,208,100.62 | 379,135,177.06 |
| 少数股东损益 | 63,433,424.21 | 37,855,212.37 | 94,448,648.83 | 89,974,972.15 |
| 扣除非经常损益后的净利润 | 253,163,961.29 | 135,828,348.93 | 249,284,664.96 | 276,937,850.51 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.21 | 0.1 | 0.28 | 0.27 |
| (二)稀释每股收益 | 0.21 | 0.1 | 0.28 | 0.27 |
| 八、其他综合收益 | -35,537.68 | -20,777.29 | -5,987.04 | - |
| 归属于母公司股东的其他综合收益 | -35,537.68 | -20,777.29 | -5,987.04 | - |
| 九、综合收益总额 | 355,347,026.81 | 178,209,212.82 | 487,650,762.41 | 469,110,149.21 |
| 归属于母公司股东的综合收益总额 | 291,913,602.6 | 140,354,000.45 | 393,202,113.58 | 379,135,177.06 |
| 归属于少数股东的综合收益总额 | 63,433,424.21 | 37,855,212.37 | 94,448,648.83 | 89,974,972.15 |
| 公告日期 | 2026-08-26 | 2026-04-28 | 2026-04-24 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |